142
Participants
Start Date
March 22, 2019
Primary Completion Date
October 2, 2021
Study Completion Date
October 2, 2021
TVB-2640 25 mg (US)
Oral dose, tablet, daily dosing
TVB-2640 50 mg (US)
Oral dose, tablet, daily dosing
Placebo (US)
Oral dose, tablet, daily dosing
TVB-2640 50 mg (China)
Oral dose, tablet, daily dosing
Placebo (China)
Oral dose, tablet, daily dosing
TVB-2640 75 mg (US)
Oral dose, tablet, daily dosing
Lucas Research, Morehead City
Panax, Miami Lakes
Texas Digestive Disease Consultants - Dallas, Dallas
Texas Digestive Disease Consultant - Ft Worth, Fort Worth
Texas Digestive Disease Consultants - Webster, Webster
Pinnacle Clinical Research - San Antonio, San Antonio
Texas Digestive Disease Consultants - Cedar Park, Cedar Park
Texas Diabetes and Endocrinology - Austin, Austin
Catalina Research Institute, Montclair
ProSciento, Chula Vista
University of California San Diego (UCSD), San Diego
Clinical Trials Research, Sacramento
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing YouAn Hospital, Capital Medical University, Beijing
Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
Shanghai Tongren Hospital, Shanghai JiaoTong University School of Medicine, Shanghai
The Second Hospital of Nanjing, Nanjing
The Affiliated Hospital of Hangzhou Normal University, Hangzhou
Nanfang Hospital, Guangzhou
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou
The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou
Foshan First People's Hospital, Foshan
Sagimet Biosciences Inc.
INDUSTRY